SNY
Sanofi
SNY's fundamentals are mixed: it turned 24% of its revenue into free cash flow, but its operating margin fell 4 points to 15%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SNY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Healthy |
SNY's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
SNY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $5.73 | -88% |
| Fair | 19x | $10.07 | -79% |
| Expensive | 31x | $16.50 | -66% |
| Current | 89x | $48.46 | — |
Historical ranges are pointers, not guarantees.
SNY's PE is 89x, but its earnings don't support one, so it isn't a reliable read right now.
SNY Forward outlook
There aren't enough analyst estimates for SNY to show an outlook.
SNY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.54 | -87% |
| Q1 2026 | $2.17 | -27% |
| Q4 2025 | $2.27 | -15% |
| Q3 2025 | $4.28 | +112% |
| Q2 2025 | $4.27 | +127% |
| Q1 2025 | $2.99 | +49% |
| Q4 2024 | $2.66 | +11% |
| Q3 2024 | $2.02 | -50% |
SNY's earnings per share have fallen from their peak: $0.54 over the past year, against $5.47 in late 2020.
SNY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $13.7B | +15% |
| Q1 2026 | $12.5B | +6% |
| Q4 2025 | $13.6B | +60% |
| Q3 2025 | $14.6B | -7% |
| Q2 2025 | $11.9B | -5.7% |
| Q1 2025 | $11.8B | +9% |
| Q4 2024 | $8.5B | -37% |
| Q3 2024 | $15.7B | +11% |
SNY's revenue has picked up after three years of holding roughly level: $13.7B last quarter, up 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 19% | +5.6 points |
| Q1 2026 | 20% | -0.9 points |
| Q4 2025 | -8.5% | -16 points |
| Q3 2025 | 28% | +1.8 points |
| Q2 2025 | 14% | -0.3 points |
| Q1 2025 | 21% | +8.3 points |
| Q4 2024 | 7.5% | +4.7 points |
| Q3 2024 | 26% | +0.4 points |
SNY's operating margin was 19% last quarter, up 5.6 points from the same quarter a year ago.
SNY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $4.3B | +$4.3B |
| Q1 2026 | $1.9B | -20% |
| Q4 2025 | $1.8B | +$1.8B |
| Q3 2025 | $5.1B | +$5.1B |
| Q2 2025 | $0 | +$458.7M |
| Q1 2025 | $2.3B | +$2.3B |
| Q4 2024 | $0 | -100% |
| Q3 2024 | $0 | $0 |
SNY generated $13.1B in free cash flow over the past year, about six times what it generated the year before.
SNY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -15.2M shares |
| 1 year | -3% | -74.6M shares |
| 3 years | -4.3% | -108M shares |
| 5 years | -4.4% | -111M shares |
| Available history | -4.4% | -111M shares |
SNY has 2.4B diluted shares, down 3% from a year ago, with $1.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | $1.3B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $32.2M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
SNY spent $1.3B buying back its own shares over the past year, after none the year before.
SNY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.0x | Healthy |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 1.0x | Healthy |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 1.1x | Healthy |
| Q4 2024 | 1.0x | Very low |
| Q2 2024 | 2.1x | Moderate |
SNY's net debt is about 1.2 years of its operating earnings (EBITDA), up from less than a year a year ago.
SNY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.1 | Neutral |
| Stochastic | 86.8 | Overbought |
SNY's weekly RSI is 64 (neutral) and its Stochastic is 87 (overbought).
SNY PE vs Healthcare Sector
| Metric | SNY | Sector median | Relative |
|---|---|---|---|
| PE | 89x | 26x | 244% above |
| PE % | 100 | 29 | 71 pts above |
SNY is trading at 89x earnings, a 244% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
SNY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $42.9 | 13% above |
| 20 week MA | $43.4 | 12% above |
| 50 week MA | $45.1 | 7.5% above |
| 100 week MA | $47.9 | 1.1% above |
| 200 week MA | $49.4 | 1.9% below |
SNY has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 1.9% below its 200-week average.
SNY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $50.9 | $47.5 | -6.7% |
| 2021 | $47.5 | $49.8 | +5% |
| 2022 | $49.8 | $48.5 | -2.6% |
| 2023 | $48.5 | $49.7 | +2.5% |
| 2024 | $49.7 | $48.7 | -2% |
| 2025 | $48.7 | $48.5 | -0.5% |
| 2026 YTD | $48.5 | $48.5 | 0% |
SNY has finished lower in four of the last six years. It's roughly flat so far in 2026.